BioCentury | Sep 3, 2019
Company News

Sept. 3 Company Quick Takes: Mundipharma-Cidara, Roche-Spark, Vascepa

...Mundipharma licenses rights to Cidara’s rezafungin Cidara Therapeutics Inc. (NASDAQ:CDTX) granted Mundipharma International Ltd. (Dublin, Ireland...
...Therapeutics Inc. (NASDAQ:CDTX) granted Mundipharma International Ltd. (Dublin, Ireland) exclusive rights to develop and commercialize rezafungin...
...of the therapy in Europe by year end to reduce CV events. BioCentury Staff rezafungin (CD101 IV, biafungin, sp 3025) Vascepa...
BioCentury | Jul 31, 2019
Clinical News

July 30 Clinical Quick Takes: Biogen, Alkermes MS candidate superior to Tecfidera; plus Amgen, Lilly and more

...meets in Phase II Cidara Therapeutics Inc. (NASDAQ:CDTX) said Monday that once weekly rezafungin (formerly CD101 IV...
...receiving 400 mg rezafungin per dose; and 6.7% and 86.7% in patients receiving an initial rezafungin...
...ligand 1; TIM3 (HAVCR2) - T cell immunoglobulin and mucin domain 3 BioCentury Staff KSI-301 rezafungin (CD101 IV, biafungin, sp 3025) Vumerity...
BioCentury | Apr 20, 2018
Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

...population of the Phase II STRIVE trial showing that once-weekly 400 mg IV rezafungin (formerly CD101 IV...
...Diego, Calif. Product: Rezafungin (formerly CD101 IV) Business: Infectious Molecular target: NA Description: IV formulation of biafungin...
...candidiasis; survival Status: Phase II data Milestone: Start Phase III (mid-2018) Elizabeth S. Eaton rezafungin (CD101 IV, biafungin, sp 3025) Cidara...
BioCentury | Feb 24, 2017
Clinical News

CD101 Topical: Phase II RADIANT data

...candidiasis. The company said the discontinuation of CD101 topical will not impact its development of CD101 IV...
...Calif. Product: CD101 topical (formerly Topifungin) Business: Infectious Molecular target: NA Description: Topical formulation of biafungin...
BioCentury | Feb 21, 2017
Clinical News

Cidara discontinues CD101 topical for vulvovaginal candidiasis

...no serious adverse events reported. The product is a topical formulation of the echinocandin antifungal biafungin...
...Phase II STRIVE trial of CD101 IV to treat candidemia are expected in 4Q17. Jaime De Leon CD101 CD101 IV CD101 topical SP 3025 Cidara...
BioCentury | Jun 20, 2016
Clinical News

CD101 topical: Phase II started

...Product: CD101 topical (formerly Topifungin ) Business: Infectious Molecular target: NA Description: Topical formulation of biafungin...
BioCentury | Jun 6, 2016
Clinical News

CD101 topical regulatory update

...RADIANT trial of CD101 topical to treat VVC. The product is a topical formulation of biafungin...
BioCentury | Jan 18, 2016
Clinical News

CD101 IV: Phase I data

...trial in 24 healthy volunteers showed that multiple doses of 100, 200 and 400 mg CD101 IV...
...were reported. Patients in the 100 and 200 mg dose cohorts received 2 doses of CD101 IV...
...with Candida infections. Cidara Therapeutics Inc. (NASDAQ:CDTX), San Diego, Calif. Product: CD101 IV (formerly Biafungin , SP 3025...
BioCentury | Sep 28, 2015
Clinical News

Cidara Therapeutics preclinical data

...by year end. Cidara Therapeutics Inc. (NASDAQ:CDTX), San Diego, Calif. Product: CD101 IV (formerly Biafungin , SP 3025...
BioCentury | Sep 7, 2015
Clinical News

CD101 IV: Phase I started

...32 healthy volunteers. Cidara Therapeutics Inc. (NASDAQ:CDTX), San Diego, Calif. Product: CD101 IV (formerly Biafungin , SP 3025...
Items per page:
1 - 10 of 16